ABOS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

ABOS ▼ -12.10% at T+5d

NEUTRAL call ✗ call lost -12.10% · α vs SPY -12.17% · entry $2.48 → $2.18

Next anchor: T+20d due 5d ago

Last close $2.37 (close Jun 12) · -4.44% from $2.48 entry

Entry anchored
May 11, 03:59 PM ET
via Databento tick

T+1d

+0.40%

call +0.40% · α -0.17%

$2.49

settled 5w ago

T+5d

-12.10%

call -12.10% · α -12.17%

$2.18

settled 27d ago

T+20d

—

call — · α —

—

due 5d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowing to $20.7M from $28.8M YoY. Cash balance increased to $128.4M following a $35.75M private placement, funding operations into early 2027. The stock will move on the EPS beat and cash runway extension, but the primary catalyst remains the ALTITUDE-AD Phase 2 topline results expected in late 2026.

Actionable Insight

The EPS beat and cash runway extension are positive but the stock remains a binary event play on ALTITUDE-AD topline results in late 2026. Monitor for any early data disclosures or enrollment updates that could derisk the program. The EBD option exercise in Q2 2026 may provide a near-term catalyst.

Key Facts

Q1 2026 GAAP EPS -$0.33 vs consensus -$0.46 (28.3% beat)
Net loss $20.7M vs $28.8M YoY, improved 28.1%
Cash, equivalents and marketable securities $128.4M as of Mar 31, 2026, up from $116.9M at Dec 31, 2025
Private placement in March 2026 raised $35.75M in gross proceeds
R&D expenses fell to $16.5M from $25.3M YoY due to lower manufacturing and CRO costs
ALTITUDE-AD Phase 2 topline results expected in late 2026
Option to license up to two EBD program candidates expected in Q2 2026
IND filing for lead EBD candidate targeted for mid-2027

Financial Impact

EPS beat of $0.13 vs consensus; net loss improved by $8.1M YoY; cash runway extended into early 2027

epsnetLosscashPositionrndExpenses

Risk Factors

ALTITUDE-AD Phase 2 failure would likely wipe out most of the company's value
Cash runway only into early 2027 — additional financing likely needed before results
Pre-revenue biotech with no approved products; high clinical and regulatory risk
Historical stock moves have been highly volatile with negative T+20 alpha

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

92% bullish (12 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3292642

6 reports for ABOS

T+1T+5T+20T+60

Filters

Reports for ABOS — sortable, filterable
	Type				Now
May 12, 2026 4w ago	8-K NEUTRAL ★ 3/10	$2.48 $2.18	▼ −12.10%	▼ −12.17%	$2.37 (−4.44%)
May 12, 2026 4w ago	Press Release NEUTRAL ★ 5/10	$2.48 $2.18	▼ −12.10%	▼ −12.17%	$2.37 (−4.44%)
Mar 26, 2026 11w ago	S-3 NEUTRAL ★ 5/10	$2.26 $2.76	▲ +22.12%	▲ +18.26%	$2.37 (+4.87%)
Mar 26, 2026 11w ago	Press Release MIXED ★ 6/10	$2.55 $2.70	▲ +5.88%	▲ +4.25%	$2.37 (−7.06%)
Mar 19, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$2.67 $2.26	▼ −15.36%	▼ −13.21%	$2.37 (−11.24%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$3.34 $2.71	▼ −18.86%	▼ −16.82%	$2.37 (−29.04%)

US Market Status

Market Closed — Opens in 4h 44m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access